<?xml version="1.0" encoding="UTF-8"?>
<ref id="B51-antioxidants-09-00660">
 <label>51.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Parlar</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Arslan</surname>
    <given-names>S.O.</given-names>
   </name>
   <name>
    <surname>Dogan</surname>
    <given-names>M.F.</given-names>
   </name>
   <name>
    <surname>Cam</surname>
    <given-names>S.A.</given-names>
   </name>
   <name>
    <surname>Yalcin</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Elibol</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>Ozer</surname>
    <given-names>M.K.</given-names>
   </name>
   <name>
    <surname>Uckardes</surname>
    <given-names>F.</given-names>
   </name>
   <name>
    <surname>Kara</surname>
    <given-names>H.</given-names>
   </name>
  </person-group>
  <article-title>The exogenous administration of CB2 specific agonist, GW405833, inhibits inflammation by reducing cytokine production and oxidative stress</article-title>
  <source>Exp. Ther. Med.</source>
  <year>2018</year>
  <volume>16</volume>
  <fpage>4900</fpage>
  <lpage>4908</lpage>
  <pub-id pub-id-type="doi">10.3892/etm.2018.6753</pub-id>
  <?supplied-pmid 30542446?>
  <pub-id pub-id-type="pmid">30542446</pub-id>
 </element-citation>
</ref>
